128 related articles for article (PubMed ID: 9160526)
1. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations.
Todd CW; Pozzi LA; Guarnaccia JR; Balasubramanian M; Henk WG; Younger LE; Newman MJ
Vaccine; 1997 Apr; 15(5):564-70. PubMed ID: 9160526
[TBL] [Abstract][Full Text] [Related]
2. Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly.
Newman MJ; Todd CW; Lee EM; Balusubramanian M; Didier PJ; Katz JM
Mech Ageing Dev; 1997 Feb; 93(1-3):189-203. PubMed ID: 9089583
[TBL] [Abstract][Full Text] [Related]
3. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.
Brewer JM; Conacher M; Satoskar A; Bluethmann H; Alexander J
Eur J Immunol; 1996 Sep; 26(9):2062-6. PubMed ID: 8814247
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein Formulations.
Chisholm CF; Nguyen BH; Soucie KR; Torres RM; Carpenter JF; Randolph TW
J Pharm Sci; 2015 Nov; 104(11):3681-3690. PubMed ID: 26190624
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
[TBL] [Abstract][Full Text] [Related]
6. Design and development of adjuvant-active nonionic block copolymers.
Newman MJ; Todd CW; Balusubramanian M
J Pharm Sci; 1998 Nov; 87(11):1357-62. PubMed ID: 9811490
[TBL] [Abstract][Full Text] [Related]
7. Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways.
Ke Y; McGraw CL; Hunter RL; Kapp JA
Cell Immunol; 1997 Mar; 176(2):113-21. PubMed ID: 9073383
[TBL] [Abstract][Full Text] [Related]
8. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice.
Katz JM; Lu X; Todd CW; Newman MJ
Vaccine; 2000 Apr; 18(21):2177-87. PubMed ID: 10717336
[TBL] [Abstract][Full Text] [Related]
9. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses.
Lanier JG; Newman MJ; Lee EM; Sette A; Ahmed R
Vaccine; 1999 Oct; 18(5-6):549-57. PubMed ID: 10519946
[TBL] [Abstract][Full Text] [Related]
11. The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant.
Beck L; Spiegelberg HL
Cell Immunol; 1989 Oct; 123(1):1-8. PubMed ID: 2776217
[TBL] [Abstract][Full Text] [Related]
12. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.
Wafa EI; Geary SM; Goodman JT; Narasimhan B; Salem AK
Acta Biomater; 2017 Mar; 50():417-427. PubMed ID: 28063991
[TBL] [Abstract][Full Text] [Related]
13. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
14. The selection of an adjuvant emulsion for polyclonal antibody production using a low-molecular-weight antigen in rabbits.
Smith DE; O'Brien ME; Palmer VJ; Sadowski JA
Lab Anim Sci; 1992 Dec; 42(6):599-601. PubMed ID: 1479813
[TBL] [Abstract][Full Text] [Related]
15. Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice.
Yamaki K; Alam AH; Hossain MA; Taneda S; Yanagisawa R; Takano H; Yoshino S
Scand J Immunol; 2005 Oct; 62(4):378-84. PubMed ID: 16253125
[TBL] [Abstract][Full Text] [Related]
16. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers.
Hunter RL; Bennett B
J Immunol; 1984 Dec; 133(6):3167-75. PubMed ID: 6491284
[TBL] [Abstract][Full Text] [Related]
17. Development of vaccines based on formulations containing nonionic block copolymers.
Brey RN
Pharm Biotechnol; 1995; 6():297-311. PubMed ID: 7551222
[TBL] [Abstract][Full Text] [Related]
18. OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis.
Yanase N; Toyota H; Hata K; Yagyu S; Seki T; Harada M; Kato Y; Mizuguchi J
Vaccine; 2014 Oct; 32(45):5918-24. PubMed ID: 25211769
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
[TBL] [Abstract][Full Text] [Related]
20. Systematic development of a block copolymer adjuvant for trivalent influenza virus vaccine.
Todd CW; Lee E; Balusubramanian M; Shah H; Henk WG; Younger LE; Newman MJ
Dev Biol Stand; 1998; 92():341-51. PubMed ID: 9554290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
